22 per cent of people on Incapacity Benefit (Employment Support Allowance) have a musculoskeletal disorder.
Across the EU, 25% of workers complain of back ache and 23% report muscular pains at a single point in time.
In the UK, each person with a musculoskeletal disorder took an estimated 17.2 days off sick in 2008/09 (2).
At the Back and Body Clinic we understand that a healthy and happy workplace results in:
- Reduced time off work
- Improved employee job satisfaction
- Improved workplace outcomes
Back and neck pain is extremely common. It is seen not only in those who perform physically demanding work, but more and more amongst workers who spend a prolonged time in static positions, such as office workers.
The Back and Body Clinic’s corporate physiotherapy package options provide onsite or offsite hands-on physiotherapy treatment to assist with the prevention and treatment of these conditions.
Research by Price Waterhouse Cooper for the Department of Work and Pensions found consistent evidence that health and well being initiatives reduced absence rates and improved productivity in all 55 different companies researched(3)..
The Work Foundation concluded that for every £1 invested in wellbeing initiatives, businesses get a return of £3(1). At the Back and Body Clinic we work with companies in Northampton to provide specialist therapy services. We would welcome the opportunity to talk to you more about different options and packages we offer to you and your workforce.
Whilst anyone can benefit from corporate physiotherapy, there are specific work environments where employees are at most risk. These can include:
- Workers who travel extensively
- Workers who sit in front of a laptop or desktop for long periods
- Workers who have long work hours or put in overtime
- Workers who perform repetitive tasks
- Workers who have manual handling tasks
Below are just two examples of well known companies who have introduced corporate physiotherapy and monitored the benefits:
Case Study 1: The Royal Mail(4)
Introduced an occupational support and therapy programme
Reported substantial financial benefits
Return of approximately £5 for every £1 invested
Absence was cut by 25 per cent between 2004 and 2007
Case Study 2: AstraZeneca(5)
AstraZeneca started its “Wellbeing” programme for its 10,000 staff in the UK in 2000
Provision of: Treatment services such as physiotherapy, Health promotion such as sports facilities, Health screening
The company saved £200,000 a year
Absence levels 31 per cent lower than average levels
The Back and Body Clinic is ideally placed to:
- Help keep your employees healthy
- Enable the employee to understand prevention of disease chronicity, re-occurrence, and strategies to self-manage effectively
- Design bespoke multidisciplinary packages of care
- Enhance productivity in the work place
- Reduce Days off Sick
- Speed up return to work
- Save your company money
We would welcome the opportunity to come and discuss corporate physiotherapy further with you and design a bespoke package of care for your company.
Please email us at firstname.lastname@example.org requesting a phone call or a meeting, or fill out the ‘request an appointment’ form at the bottom of the page.
1. Bevan S, Quadrello T, McGee R. Fit for work? Musculoskeletal disorder and the European workforce. London: The Work Foundation; 2009 URL: www.theworkfoundation.com/research/publications/publicationdetail.aspx?oItemId=44&parentPageID=102&PubType
2. Boorman S. NHS health and well-being review: interim report. London: Department of Health; 2009 URL: www. nhshealthandwellbeing.org/pdfs/NHS%20Staff%20H&WB%20 Review%20Final%20Report%20VFinal%2020-11-09.pdf
3. PricewaterhouseCoopers. Building the case for wellness: 4th February 2008. London: PricewaterhouseCoopers; 2008.URL: www. dwp.gov.uk/docs/hwwb-dwp-wellness-report-public.pdf
4. Marsden D, Moriconi S. The value of rude health: report for the Royal Mail group. London: LSE Enterprise; 2008. URL: http://eprints.lse.ac.uk/5148/
5. Well-being in AstraZeneca – case study. URL: www. hse.gov.uk/business/casestudy/astrazeneca.htm